



This is to certify that :

DR. dr. Ago Harlim, MARS, SpKK

has attended as a

Speaker

Teaching Class

INTERNATIONAL SCIENTIFIC MEETING ON COSMETIC DERMATOLOGY

BOROBUDUR HOTEL | JAKARTA • JANUARY 31st, 2019

SK PB IDI No. : 0114/PB/A.4/01/2019 Participant : 6 SKP, Speaker : 14 SKP, Moderator : 6 SKP, Committee : 3 SKP

DR. Dr. M. Yulianto Listiawan, Sp.KK(K), FINSDV, FAADV President of PERDOSKI

Dr. Abraham Arimuko, SpKK, MARS, FINSDV, FAADV President of KSDKI



INTERNATIONAL SCIENTIFIC MEETING ON COSMETIC DERMATOLOGY BOROBUDUR HOTEL | JAKARTA • 31 JANUARY - 2 FEBRUARY 2019

www.iscod.id

Accredited by :











V

ORGANIZING AND SCIENTIFIC COMMITTEE

ORGANIZING COMMITTEE

Patron

- President of Indonesian Medical Association (IDI)
- President of Indonesian Society of Dermatology and Venereology (PERDOSKI)

Advisor

Dr. Sjarif M. Wasitaatmadja, SpKK (K), FINSDV, FAADV

Chairman

Dr. Abraham Arimuko, SpKK, MARS, FINSDV, FAADV

Secretaries

Dr. Brahm U. Pendit, Sp.KK, FINSDV Dr. Hanny Nilasari, Sp.KK(K), FINSDV, FAADV Dr. Sukirman, Sp.KK, M. Kes

Treasures

Dr. I Dewa Ayu Supriyantini, M.Biomed, Sp.KK Dr. Tia Febrianti, Sp.KK, FINSDV, FAADV

Fund Raising

Dr. Lilik Norawati, Sp.KK, FINSDV, FAADV Dr. Andreas Widiansyah, Sp.KK, FINSDV, FAADV

Scientific

Dr. Sjarif M. Wasitaatmadja, Sp.KK(K), FINSDV, FAADV Dr. Danang Triwahyudi, Sp.KK, FINSDV, FAADV DR. Dr. Irma Bernadette, Sp.KK(K), FINSDV, FAADV Dr. Lili Legiawati, Sp.KK(K), FINSDV, FAADV Dr. Amaranila L. Drijono, Sp.KK(K), FINSDV, FAADV Dr. Susanti Budiamal, Sp.KK, FINSDV, FAADV Dr. Rina Dewi, SpKK Dr. Githa Rahmayunita, SpKK, FINSDV, FAADV

International Relation

Dr. Srie Prihianti, SpKK, PhD, FINSDV, FAADV

Teaching Class

Dr. Widyo Atmoko, Sp.KK, FINSDV Dr. Andreas Widiansyah, Sp.KK, FINSDV, FAADV Dr. Dian Pratiwi, Sp.KK, FINSDV, FAADV

Symposia

Dr. Silvia Veronica, SpKK, FINSDV Dr. Fitria Agustina, SpKK, FINSDV

Program

Dr. Rita Maria, SpKK Dr. I Ketut Sukarata, Sp.KK, FINSDV, FAADV

Exhibition

Dr. Brahm U. Pendit, Sp.KK, FINSDV Dr. Widyo Atmoko, Sp.KK, FINSDV Dr. Roro Inge Krisanti, Sp.KK, FINSDV, FAADV

Accomodation and Transportation

Dr. Afaf Agil Al Munawwar, SpKK Dr. Shalina Sebayang, Sp.KK, FINSDV, FAADV

Publication and Documentation

Dr. Diah Puspitosari, Sp.KK, FINSDV

Secretariat

Kelompok Studi Dermatologi Kosmetik Indonesia (KSDKI) Gedung Prof. dr. Satrio, Lantai 4 Departemen Kulit dan Kelamin, RSPAD Gatot Soebroto JL Abdulrahman Saleh No. 24, Jakarta Pusat. Telp/Fax 021-3510837 Email iscodksdki@gmail.com payment.iscod@gmail.com abstract.iscod2019@gmail.com Website www.iscod.id

Contact Persons:

(ISCoD

- Novi : +62 812 1087 9662
- Diah : +62 852 8677 3947
- Vivi : +62 858 8989 0855

INTERNATIONAL SCIENTIFIC MEETING ON COSMETIC DERMATOLOGY

BOROBUDUR HOTEL 31 JANUARY - 2 FEBRUARY 2019

SCIENTIFIC PROGRAMME

TEACHING CLASS (Hotel Borobudur) Thursday, 31 Januari 2019

TIME	ICA	TCB	TCC
	SUMBA A	SUMBA B	STIMPA C
07.00 - 08.00		Re-Registration	SOMBAC
	Botulinum toxin	Chamical and	
08.0 - 08.30	Injection technique for botulinum toxin Stanley Setiawan	Chemical peel for acne Nestor Torres	Acne Scar Development and Pathogenesis of Acne Scar Theresia Lumban Toruan
08.30 - 09.00	Danger area for botulinum toxin injection Edwin Djuanda	Chemical peel for pigmentation Nestor Torres	Topical Growth Factor for Acne Scar Lilik Norawati
09.00 - 09.30	Botulinum toxin injection complication Andreas Widiansyah	Chemical peel for aging Nestor Torres	Selective sebaceous gland electrothermolysis as a treatment for acne Silvia Veronica
09.30 - 10.00		COFFEE BREAK	
	Filler	Acne	Pigmentation
10.00 - 10.30	Improving Skin Elasticity with Hyaluronic Acid Era Jusi Nasution	Indonesian Acne Guidelines Irma Bernadette	Topical application for skin hyperpigmentation Sjarif M. Wasitaatmadja
10.30 - 11.00	Nasolabial Line Filler LisSurachmiati	Management severe acne GohCheeLeok	Adjuvant therapy for skin pigmentation Dwi RetnoAdiwinarni
11.00 - 11.30	Restoring Youth and Enhancing Cheek with Anterior Cheek Filler Era Jusi Nasution	Management Post acne sequele Peachy Lao	Systemic and comprehensive approach for skin pigmentation Cheong WaiKwong
11.30 - 12.30		LUNCH	
	Dermatologic Surgery	Dermatologic Laser	Mod. Dr Brahm U Pendit
12.30 - 13.00	Complication in Dermatologic Surgery : How to treat infection Susanti Budiamal	Laser and EBD for pigmented problem and Melasma Aryani Sudharmono	 Free Paper Oral Presentation Patient Selection For Happy Lift[®] (Revitalizing) And Skinfill[®] Diamond Plus: An Important Consideration. <u>Nelson Chang</u>. Hong Kong. The Efficacy And Safety Of Plant Oil Mixtures In The Treatment Of Xerosis With Prurity Senilis For Eldedy.
13.00 - 13.30	Complication in Dermatologic Surgery : How to treat miscellaneous Larisa Paramitha	Laser and EBD for the Revision of Athropic Acne Scar David Sudarto Oeiria	 Randomized Controlled Trial. <u>Yulia Farida Yahya</u>. Palembang. Esthetic Approach To Severe HirsutismOf A Rare Hepatic Adrenal Rest Tumor In A 22-Year-Old Woman. <u>Kartika</u> <u>Ruchiatan</u>, Bandung.
13.30 - 14.00	How I correct a chin siliconoma Ago Harlim	Laser and EBD for skin rejuvenation AmaranilaLalitaDrijono	 Oral Cyclosporine Treatment In Alopecia Areata Multifocal Patchy Type: A Case Report, <u>Prasta Bayu Putra</u>, Yogyakarta Combination Medium-Depth Chemical Peels With Jessner Liquid And Trichloroacetic Acid 35% In Patient With Favre-Racouchot Syndrome. <u>Yogya Yuri</u>, Bandung. Combination Of Tranexamic Acid Intradermal Injection And Q-Switched Nd:Yag 1064 Nm Laser In Mixed Type Melasma. <u>Sinta Murlistyarini</u>. Malang. The Effectiveness Of Combination Therapy With Topical, Systemic, And Pulsed-Dye Laser On Papulopustular
			Rosacea, <u>Kartika Ruchiatan</u> , Bandung 8. Two Case Of Face Skin Rejuvination With Laser Ablative

And Microneedling. Khathreen Corry, Bali 9. Papular Eruption Associated With Epidermal Growth Factor Receptor Inhibitor. Hanif Sri Utami, Jakarta





CONTENT:

GREETING CHAIRMAN OF ORGANIZING COMMITTEE	EXEROSIS-
WELCOME MESSAGE The President of INSDV	
RUNDOWN	
CONTENT	
	XII
TEACHING CLASS	0.049 .444
INJECTION TECHNIQUE FOR BOTULINUM TOXIN	
DANGER AREA FOR BOTULINUM TOXIN INIECTION	
BOTULINUM TOXIN INJECTION COMPLICATION	C nonementeren C
IMPROVING SKIN ELASTICITY WITH HYALURONIC ACID.	4 E
NASOLABIAL LINE FILLER	J
RESTORING YOUTH AND ENHANCING CHEEK WITH ANTERIOR CHEEK FILLER	
COMPLICATION IN DERMATOSURGERY; HOW TO TREAT INFECTION	
HOW I CORRECT SILICON GRANULOMA IN CHIN	7
MULTIFOCAL TREATMENT TO CONTROL ACNE-PRONE SKIN	0
EFFECTIVE AND LASTING TREATMENT OF MELASMA IN PATIENTS	0
IN PATIENTS WITH A MULTI-ETHNIC PROFILE USING COSMELAN	9
COMBINATION IN CHEMICAL PEELS FOR THE TREATMENT	
OF HYPERPIGMENTED AND ANTIAGING OF THE SKIN FROM MODERATE	12
INDONESIAN CONSENSUS ON ACNE TREATMENT GUIDELINE	16
MANAGEMENT OF SEVERE ACNE VULGARIS	17
LASER AND EBD FOR PIGMENTED PROBLEM AND MELASMA	18
LASER AND EBD FOR PIGMENTED PROBLEM AND MELASMA	19
LASER AND EBD FOR SKIN REJUVENATION	20
PATHOGENESIS OF ACNE SCARS	21
COMBINATION THERAPY USING MICRONEEDLING WITH GROWTH FACTORS	
AND 15% TCA PEEL IN THE MANAGEMENT OF ATROPHIC ACNE SCARS	
SELECTIVE SEBACEOUS GLAND ELECTROTHERMOLYSIS	
AS A TREATMENT FOR ACNE	
TOPICAL APPLICATION FOR SKIN HYPERPIGMENTATION	
ADJUVANT THERAPY FOR SKIN PIGMENTATION	
SYSTEMIC AND COMPREHENSIVE APPROACH FOR SKIN PIGMENTATION	

INTERNATI	IONAL SCIE	NTIFIC MEETING
ON	COSMETIC	DERMATOLOGY



CDCC DADED 21 JANUARI 2019	27
PATIENT SELECTION FOR HAPPY LIFT™ (REVITALIZING) AND SKINFILL™ DIAMOND PLUS:	28
THE FEFICACY AND SAFETY OF PLANT OIL MIXTURES IN THE TREATMENT	
OF XEROSIS WITH SENILE PRURITUS FOR ELDERLY PATIENTS:	
RANDOMIZED CONTROLLED TRIAL	28
THE EFFICACY AND SAFETY OF PLANT OIL MIXTURES IN THE TREATMENT	
OF XEROSIS WITH SENILE PRURITUS FOR ELDERLY PATIENTS:	
RANDOMIZED CONTROLLED TRIAL	29
ORAL CYCLOSPORINE TREATMENT IN ALOPECIA AREATA MULTIFOCAL PATCHY TYPE:	
A CASE REPORT	30
COMBINATION OF MEDIUM-DEPTH CHEMICAL PEELS WITH JESSNER LIQUID AND 35%	
TRICHLOROACETIC ACID IN PATIENT WITH FAVRE-RACOUCHOT SYNDROME	30
COMBINATION OF TRANEXAMIC ACID INTRADERMAL INJECTION AND Q-SWITCHED ND:	
YAG 1064 NM LASER IN MIXED TYPE MELASMA	31
THE EFFECTIVENESS OF COMBINATION THERAPY WITH TOPICAL, SYSTEMIC,	
AND PULSED-DYE LASER ON PAPULOPUSTULAR ROSACEA	31
TWO CASES OF FACE SKIN REJUVINATION WITH LASER ABLATIVE AND MICRONEEDLING	32
PAPULAR ERUPTION ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBIT	OR33

PL	EN	ARY	SE	SSI	ΟN	-
	-					

CORAL TREND IN AESTHETIC DERMATOLOGY	34
A STHETIC TREND, UNMET NEEDS AND WHAT'S NEW	34
DERMATOLOGY IN INDONESIA.	35
COSMETIC DERMATOLOGY PROCEDURES	36

T CERPITARI 2019	
THE ADDRESS ON NOVEL ABSORBABLE BARBED THREADS	
ES IN THREAD LIFT	
EXPERT SHARING (THREADS)	
ENDOUTE BIOLOGY AND REGULATION OF PIGMENTATION SYSTEM	
PSOR GLUTATHIONE AS SKIN WHITENING AGENTS	
UPDATE IN DIAGNOSIS OF MELASMA	
AND CUTUDE PROSPECTS	
COSMECENTICAL FOR HYPERPIGMENTATION, DOES IT REALLY WORK?	
ANTI-AGING COSMECEUTICALS: HOW TO CHOOSE THE RIGHT INGREDIENTS	





FREE PAPER, 31 JANUARI 2019	27
PATIENT SELECTION FOR HAPPY LIFT™ (REVITALIZING) AND SKINFILL™ DIAMOND PLUS:	
AN IMPORTANT CONSIDERATION	28
THE EFFICACY AND SAFETY OF PLANT OIL MIXTURES IN THE TREATMENT	
OF XEROSIS WITH SENILE PRURITUS FOR ELDERLY PATIENTS:	
RANDOMIZED CONTROLLED TRIAL	28
THE EFFICACY AND SAFETY OF PLANT OIL MIXTURES IN THE TREATMENT	
OF XEROSIS WITH SENILE PRURITUS FOR ELDERLY PATIENTS:	
RANDOMIZED CONTROLLED TRIAL	29
ORAL CYCLOSPORINE TREATMENT IN ALOPECIA AREATA MULTIFOCAL PATCHY TYPE:	
A CASE REPORT	30
COMBINATION OF MEDIUM-DEPTH CHEMICAL PEELS WITH JESSNER LIQUID AND 35%	
TRICHLOROACETIC ACID IN PATIENT WITH FAVRE-RACOUCHOT SYNDROME	30
COMBINATION OF TRANEXAMIC ACID INTRADERMAL INJECTION AND Q-SWITCHED ND:	
YAG 1064 NM LASER IN MIXED TYPE MELASMA	31
THE EFFECTIVENESS OF COMBINATION THERAPY WITH TOPICAL, SYSTEMIC,	
AND PULSED-DYE LASER ON PAPULOPUSTULAR ROSACEA	31
TWO CASES OF FACE SKIN REJUVINATION WITH LASER ABLATIVE AND MICRONEEDLING	32
PAPULAR ERUPTION ASSOCIATED WITH EPIDERMAL GROWTH FACTOR RECEPTOR INHIBIT	OR 33

PLENARY SESSION:

CURRENT GLOBAL TREND IN AESTHETIC DERMATOLOGY	34
ASIAN AESTHETIC TREND, UNMET NEEDS AND WHAT'S NEW	34
COSMETIC DERMATOLOGY IN INDONESIA	35
ETHICS IN COSMETIC DERMATOLOGY PROCEDURES	36

SYMPOSIUM, 1 FEBRUARI 2019	
SCIENTIFIC REVIEW ON NOVEL ABSORBABLE BARBED THREADS	
TECHNIQUES IN THREAD LIFT	
CLINICAL EXPERT SHARING (THREADS)	
MELANOCYTE BIOLOGY AND REGULATION OF PIGMENTATION SYSTEM	
PRECURSOR GLUTATHIONE AS SKIN WHITENING AGENTS	
UPDATE IN DIAGNOSIS OF MELASMA	
EVIDENCE BASED IN ACNE TREATMENT, CURRENT STATUS	
AND FUTURE PROSPECTS	
COSMECEUTICAL FOR HYPERPIGMENTATION, DOES IT REALLY WORK?	
ANTI-AGING COSMECEUTICALS: HOW TO CHOOSE THE RIGHT INGREDIENTS	

LUNCH SYMPOSIUM

LEAKY GUT AND PREMATURE AGING	50
TOPICAL ANTI-WRINKLES	52
TOPICAL ANTI-WRINKLES	53
HOLISTIC APPROACH IN ACNE MANAGEMENT	54
DERMOCOSMETICS IN ACNE, "HELP OR HOAX?"	55
LASER TREATMENT FOR FACIAL INFLAMMATORY ACNE VULGARIS	56
SYNERGISTIC APPROACH TO REACH OPTIMAL	
CLINICAL RESULTS FOR ACNE SCAR	. 57
CASE REPORT: CLINICAL AND HISTOPATHOLOGICAL	
EVALUATION OF STRIAE ALBAE TREATMENT	. 58
GROWTH FACTORS: HARNESSING HEALING POWER, FROM RESTORATION TO REJUVENATION	59
THE EFFICACY IN TREATMENT OF ACNE SCARS WITH	
NANO-FRACTIONAL RADIOFREQUENCY SYSTEM	. 60
SAFETY CONCEPT OF BODY CONTOURING PROCEDURES	. 61
UNDERSTANDING AUGMENTATION RHINOPLASTY CONCEPT	. 62
SIMPLE AND EFFECTIVE LIPOSUCTION IN DERMATOLOGIST HAND	. 63
TREATMENT OF SCARS (CAESAREAN, POST-ACNE, POST-OPERATIE)	
USING RF CANNULA	.64
LASER FOR PIGMENTED PROBLEM AND MELASMA	.65
TREATMENT OF EYEBAG USING RF CANNULA	. 66
COSMECEUTICALS FOR AGED SKIN	. 67
THE USE OF ORAL AND TOPICAL ASTAXANTHIN AT VARIOUS SKIN CONDITIONS	.68
EFFICACY OF GROWTH FACTOR IN MANAGEMENT	
OF POST ACNE HYPOTROPHIC SCAR	69
DEVELOPMENT OF HIGHLY STABLE GROWTH FACTORS	
AND THEIR APPLICATIONS TO WOUND HEALING AND ANTI-HAIR LOSS	70
CHOOSING THE RIGHT ANTIOXIDANT FOR SKIN AGING	71
THE ROLE OF TOPICAL PHYYTOESTROGEN AS AN ANTI AGING THERAPY	72
THE COMBINATION OF CERAMIDE AND UREA	
TO MOISTURSE GERIATRIC PATIENTS	73
VITILIGO UPDATE	74
COMMON HYPOPIGMENTARY DISORDERS	75
MANAGEMENT OF HYPERPIGMENTATION IN SPECIAL AREAS	76
COSMETICS IN CHILDREN	77
PREPUBERTAL ACNE	78

FREE PAPER, 1 FEBRUARY 2019	
THE DIAGNOSTIC CONUNDRUM OF RIEHL'S MELANOSIS AND OTHER	
FACIAL PIGMENTARY DISORDERS: A CASE WITH OVERLAPPING CLINICAL,	
DERMOSCOPIC, AND HISTOPATHOLOGICAL FEATURES	
SYSTEMIC GLUTATHIONE AS LIGHTENING AGENT IN ADULTS	
TREATING ASHY DERMATOSIS WITH CLOFAZIMINE	
AND QS NDYAG LASER: A CASE REPORT	
MICRONEEDLING AND PLATELET-RICH PLASMA VS MICRONEEDLING	
AND TOPICAL MINOXIDIL 5% THERAPY IN MALE PATTERN HAIR LOSS	
IMPROVEMENT OF FACIAL AGING AFTER COMBINATION OF ERBIUM-DOPED	
YTTRIUM-ALUMINIUM-GARNET (ER:YAG) AND LONG PULSED	
NEODYMIUM-DOPED YTTRIUM-GARNET (LP ND:YAG)	
LASER TREATMENT IN INDONESIAN SKIN TYPE: A SERIAL CASE REPORT	
TRICHOSCOPY AS DIAGNOSTIC AND TREATMENT EVALUATION TOOL	
IN TELOGEN EFLUIUM: A CASE REPORT	
TREATMENT CHALLENGE: OPHIASIS TYPE OF ALOPECIA AREATA	
VELLUS HAIR CYST THAT WAS INITIALLY DIAGNOSED AS STEATOCYSTOMA	
MULTIPLEX AND TREATED WITH CO2 LASER	
COMBINING TREATMENT OF BASIC PROTOCOL FOR MELASMA	
WITH YELLOW LIGHT DIODE LASER 577 NM.	
GMENTED PROBLEM AND MELASMA	
SYMPOSIUM, 2 FEBRUARI 2019	
PROTOCOL IN COMBINATION AESTHETIC MODALITIES.	
CLINICAL EXPERT SHARING	
CLINICAL EXPERIENCE SHARING (COMBINATION WITH THREADS)	
THE MOST DISTINCTIVE HISTOPATHOLOGICAL DIAGNOSIS OF THE NAILS	
NAIL DERMOSCOPY	
MANAGEMENT OF INGROWING TOENAIL	
NON FACIAL CHEMICAL PEEL	
PRO AND CONS IN CHEMICAL PEEL	
COMPLICATION OF CHEMICAL PEEL	
SCIENCE BEHIND NOVEL HA FILLER	
FULL-FACIAL REJUVENATION TECHNIQUE WITH HA FILLER	
CLINICAL GUIDE AND INCREASING PATIENT COMFORT	
CUINICAL EXPERT SHARING (FILLER)	
UPDATE IN PATHOGENESIS OF ACNE SCAR	
ACNE SCAR AND MELASMA TREATMENT USING MICRONEEDLE	ALCONTENIZOUR
TRACTIONATED RADIOFREQUENCY	
TREATMENT OF ACNE SCARS AND SKIN REJUVENATION WITH CO2	
CLASSICAL AND FRACTIONAL CASER	
THE RULE OF NEUROPEPTIDE IN AN ITAGING MANAGEMENT	
MUISTURIZER IN SKIN AGING	109

() ISCoD





NOVEL COMBINATION OF SUNSCREEN AND NIACINAMIDE AS WHITENING	
AGENT IN ASIAN SKIN	
TREND OF DERMAL FILLER FOR FACIAL REJUVENATION	
AVOIDING AND MANAGING COMPLICATION IN FILLER AND THREADS	
COMBINATION FILLER AND THREAD LIFT IN FACIAL REJUVENATION	
CLINICAL EXPERT SHARING (FILLER/THREAD/COMBINATION)	
CLINICAL EXPERIENCE SHARING IN MANAGING MALE PATTERN HAIR LOSS	
ENHANCING HAIR GROWTH IN MALE ANDROGENETIC ALOPECIA	
BY A COMBINATION OF FRACTIONAL CO2 LASER THERAPY	
AND HAIR GROWTH FACTORS	
NON SURGICAL TREATMENT OF ALOPECIA: WHERE ARE WE NOW?	
ANTI-WRINKLE EFFICACY OF CROSS-LINKED HYALURONIC	
ACID-BASED MICROPATCH WITH ACETYL HEXAPEPTIDE-8	
AND EPIDERMAL GROWTH FACTOR ON ASIAN SKIN	
INTRA-EPIDERMAL DELIVERY OF PHYSICAL AND BIMOLECULAR	
ACTIVES FOR IMMEDIATE CUTANEOUS AESTHETIC ENHANCEMENT:	
DOES IT REALLY WORK?	
LUNCH SYMPOSIUM	
POST LASER TREATMENT MANAGEMENT	
TREND IN POTUL INUM TOYIN	122
	122
STEM CELL DROTEINS IN SKIN HEALING AND DEILIVENATION	124
STRETCHMARKS: WHAT'S NEW AT THE HORIZON2	125
THE POLE OF HYDRATION IN MANAGEMENT OF ACNE	126
OCCUPATIONAL ACNE	127
SEVERE ACKE AND OTHER RELATED SYNDROME	128
DERMATITIS IN PEDIATRIC AND ADOLESCENT	129
WHAT'S NEW IN DERMATITIS AND PIGMENTATION MANAGEMENT	130
ENHANCING THE NATURAL BEAUTY WITH COMBINING NASHA AND	
OBT FILLER TECHNOLOGY	131
RESTORING THE YOUTHFUL APPEARANCE USING NASHA	
AND OBT FILLER TECHNOLOGY.	
REFRESH AND HYDRATE THE SKIN WITH HA SKINBOOSTER	
SELECTIVE SEBACEOUS GLAND ELECTROTHEMOLYSIS AS A TREATMENT FOR ACNE	
COSMETICS FOR MUCOSA	
LIST OF SPONSOR	
LAYOUT ISCOD 1	

Kepada Yth. DR. Dr. Ago Harlim, MARS, Sp.KK di tempat

Dengan hormat,

Sehubungan dengan akan diselenggarakannya acara simposium dan pameran dermatologi kosmetik oleh Kelompok Studi Dermatologi Kosmetik Indonesia (KSDKI), bekerja sama dengan Perhimpunan Dokter Spesialis Kulit dan Kelamin Indonesia (PERDOSKI), IMCAS dan 5th APMED dengan tema *"International Scientific Meeting on Cosmetic Dermatology (ISCoD)*" pada tanggal 31 Januari – 2 Februari 2019 di Hotel Borobudur Jakarta. Bersama ini kami memohon kesediaan dokter untuk menjadi **pembicara** dalam acara tersebut pada:

"How I correct a chin siliconoma"

(Teaching Class A: Dermatologic Surgery)

Lembar pernyataan kesediaan menjadi pembicara dan *curriculum vitae* (CV) kami harapkan dapat dikirim melalui e-mail: <u>abstract.iscod2019@gmail.com</u> paling lambat tanggal **5 Desember 2018**.

Demikian surat ini dan atas kesediaan dan perhatian Dokter, kami ucapkan terima kasih.

Hormat kami,

Ketua Panitia

Dr. Abraham Arimuko, Sp.KK, MARS, FINSDV, FAADV International Scientific Meeting on Cosmetic Dermatology (ISCoD)

Kelompok Studi Dermatologi Kosmetik Indonesia (KSDKI)

Bagian Kosmetik Medik - Departemen Kulit dan Kelamin RS Pusat Angkatan Darat Gatot Soebroto, Lt.4. Jl. Abdulrahman Saleh No. 24, Senen, Jakarta Pusat, T/ F : 021-3510837



168. Surat permo...KI).doc AI

How I Correct A Chin Silicoma Ago Harlim ISCOD 2019

Objectives* (describe the learning outcomes)

A special technique to make a better result in natural shape of chin and reduce the opportunity of granuloma recurrence caused by silicone injection

Introduction

Silicone liquid injection have been used for cosmetic for more than 40 years. Many complications have been reported such as granulomatous, inflammatory responses, migration, and discoloration of the tissue. In 1992, the FDA has banned silicone liquid injection for cosmetic uses. However, silicone injection is still being practiced illegally. Liquid silicone injected to chin cause granuloma, inflammation, and a witch looked like face.

Materials / method

Many methods has been used to remove the granuloma but excision were the best among all. We used knife to do the excision, only to the granuloma without damaging the skin. The Incision from under the skin in submental area and then we cut the excess skin for make better shape of chin. Using a knife to remove silicone granuloma is better that curretation, and for the inflammation we use corticosteroid injection.

Results

Combination knife with special technique and corticosteroid injection can make a better result in natural shape of chin and reduce the opportunity of silicone granuloma recurrence.

Conclusion

Granuloma on the chin can be removed by excision with special technique which result in aesthetic and low recurrence of granuloma.

Silicone

Injectable-grade silicone for medical use has been manufactured widely since the element has been known for its stable and inert characteristics [3, 4]. It includes the use of silicone oil, which has been utilized in the treatment of complicated retinal detachment and heavy silicone oil tamponade. The treatment seems to offer promising results, particularly on improving visual acuity as well as great results on some anatomical parameters; however, there are some concerns as it may cause several complications such as cataract, increased ocular pressure, heavy silicone oil emulsification, and mild inflammatory reaction [5, 6, 7].

Injectable-grade silicone has also been widely used in the form of silicone oil injection. Some studies have suggested that it may have an essential role in reducing the risk of developing diabetic foot ulcer due to its pressure-reducing properties; therefore, it can maintain plantar tissue thickness and alleviate symptoms of diabetic foot ulcer, which may be associated with foot biomechanics [8, 9].

Although it brings advantages, silicone injection may still develop some complications, either local or systemic complications. Local complications may include formation of palpable nodule surrounding injection site, arthralgia, fatigue, electrical neuropathy, and electrical sensation [10], while systemic complications may also occur in the form of lymphadenopathy, renal disease, and hepatic disease. It indicates that the injected silicone can migrate from injection site to other organs causing local and systemic complications. An animal experimental study in mouse model may explain the

pathogenesis of such complications. The study has demonstrated that macrophage of skin tissue may engulf the injected silicone and the silicone may be distributed through lymphatic circulation, ultimately causing accumulation in lymph nodes, adrenal glands, and the kidney, liver, and spleen as well as granuloma formation in the skin [11]. Complications due to silicone injection, particularly the granuloma formation may be dose-dependent. A study by Harlim has demonstrated that granuloma formation could be developed when there is a large amount of silicone exposure as the study only found a low level of silicone without any granuloma formation in the normal skin (Figure 1) [2].

Cultural changes have been encouraging people to pursue their passion on beauty and youth; therefore, cosmeticology has been rapidly growing. With technological advances, more mixed drug ingredients have been added to cosmetic products in order to beautify their customers. Thus, it may indirectly increase the use of topical cosmetics that usually contain silicone; therefore, it will lead to increase silicone uptake to the skin. It has raised a concern that the prolonged and continuous use of cosmetics will cause granuloma formation and other chronic inflammatory effects.



Figure 1. The level of silicon (Si) in normal subjects who had never received silicone injection (never injected) and in subjects with granuloma who had received silicone injection. (cited from A Harlim, et all) [2].

Diagnosis

Granuloma is a form of localized nodular inflammation, which is found in tissues [7]. On examination, there is a tumor-like mass or node of granulation tissue with active fibroblast growth and capillaries that contain epithelial-like macrophages surrounded by mononuclear cells, lymphocytes, and sometime multinucleated Datia cells present at the central core of granuloma [16].

On clinical point of view, silicone granuloma is characterized by the presence of complications of silicone. There are usually granuloma nodes, migrating silicone, wider nose, and signs of inflammation such as redness and swelling depending on the stage.

Management

The management of silicone-induced granuloma is often difficult due to migrating silicone and some of the silicone penetrating into the skin reaching the epidermis. In general, the management of granuloma can be categorized into two, i.e., surgical and pharmacological treatments. The management of nasal silicone granuloma is adjusted for the occurring complications. We must remove granuloma, which is under the skin; afterward, we perform excision of the excessive skin or implant insertion, creating a firmer and cosmetically more attractive skin. Remaining fibrosis or granuloma can be treated using steroid injection, and laser therapy is performed for redness.

Recommendation for surgical care

Granuloma formation occurs due to the presence of foreign body. Skin granuloma will cause a cosmetic problem; therefore, it should be removed.

Preoperative preparation

The preoperative preparation is similar to all kinds of skin surgery. A consultation prior to surgical procedure is necessary so that the doctor can perform both physical and psychological evaluation for the candidate. The patient should be informed about surgical procedure and the result may not be perfect as clean silicone injection can never be performed and there is a possibility of swelling. Patients with extreme high expectation will file their complaints in the future.

During the consultation, we must find out about coagulation disorder, either primary or secondary, either due to medication of pharmacological treatment or supplementation. The patients are advised to avoid food or medication that may prolong the bleeding time within 1 or 2 weeks prior to the procedure such as anticoagulants, aspirin, ginseng, garlic, cod liver oil, anticholesterol agent, vitamin E, warfarin, and Ginkgo biloba.

Curettage procedure of nasal silicone granuloma is similar to skin graft procedure, in which the covering skin must be viable. On curettage, the skin will be thinner, and it can be necrotic if there is poor vascularization. Other issues that should come into our consideration are alcohol intake, smoking habit, metabolic disorder, and poor nutrition. Blood pressure and diabetes mellitus must be well-controlled [17, 18, 19].

Informed consent

When a skin surgeon decides to perform a surgical procedure, both doctor and patient must consequently understand the impact, risk, and advantages of the procedure. First, the doctor needs to explain the diagnosis and the procedure that will be performed. Treatment of nasal silicone injection is a combination of medical therapy and cosmetic procedure because when it is left untreated, there will be changes such as migration, granuloma, and continuous inflammation. The risks and the advantages of the procedure should be emphasized. Moreover, the procedure during the surgery and the expected result after surgery need to be explained. Possible risks that may develop such as infection and its prevention including the use of antibiotics must also be explained. Patients must know other probable risks such as bleeding, crooked nose, wound scar that probably occurs, asymmetrical nostrils, an implant impression on the skin, granuloma or fibrosis that cannot be cleaned up, persistent redness of skin color, and other modalities of treatment that need to be carried out after the surgical procedure. It should also be explained that the results probably may be imperfect, particularly for patients with unrealistic wish. Results of discussion and patient's consent are written on an informed consent form, which is subsequently signed by the doctor and patient.

Technique and procedure

Every granuloma in the skin that causes cosmetic problem must be removed. Granuloma at inflammatory phase must also be removed to prevent the extension of inflammation. Local or general anesthesia could be used for procedures of skin excision, granuloma curettage. Instruments that must be prepared included minor surgery set, which can be equipped with curettage kit for cases that need curettage.

Preoperative Planning

The management of silicone-induced granuloma depends on the affected area; however, basically a doctor will first make a design planning. Next, the doctor will perform procedures according to the design or images and following the plan that has been discussed with the patient.

Depending on the occurring complication, we evaluate whether we need to remove the excessive skin from dorsal chin after perform curettage



First, We have to make the boundary of granuloma and make the design of excision area just Under the submental crease





You have to cut the granuloma with knife jut under the skin, you have carefully this time because the knife can cut the the skin above. After that you can see the granulloma already separated from skin





After take out the granuloma by knife, and curettage on the lateral part, we can stitching it

Postoperative Management

- 1. Use nasal splint or gauze for a week to prevent splint displacement.
- 2. Prescribing antibiotics for 5–7 days.
- 3. Prescribing analgetics every 4–6 hours as necessary.
- 4. Prescribing anti-inflammatory drugs for 5-7 days.
- 5. Normal saline solution for the chin to overcome postsurgical nasal congestion.
- 6. To reduce swelling, apply cold compress to periorbital within the first 48 hours.
- 7. When sleeping, the patient should keep the head elevated approximately 45°.
- 8. If there is a seroma, we can remove it by suctioning using syringe during the follow-up visit.
- 9. Avoid any trauma for 2 weeks.
- 10. Remove the stitches on day 10–14.
- 11. Have a normal diet, but avoid foods that cause excess lip movement such as apples and corn on the cob for 2 weeks after surgery.

Adjunctive Therapy to Overcome Other Complications

The principle of therapy in managing patients with granuloma due to silicone injection is preventing the development of inflammation as it will cause extention of damage.

Evacuation of silicone-induced granuloma should be performed since the liquid silicone in the tissue is persistent and will continuously induce immune response. Although the granuloma has been excised, the remaining silicone, which has migrated to all direction and has been absorbed in the skin, cannot be removed, and therefore, it may cause recurrent granuloma. The remaining inflammation, both granuloma and fibrosis, requires further treatment.

For granuloma or fibrosis that cannot be removed by surgical procedure, other modalities are required to treat the remaining fibrosis and inflammation that can still be seen on the skin, i.e., skin redness and telangiectasia.

Fibrosis and remaining granuloma

Some case reports suggest that to treat silicone-induced granuloma, intralesion injection can be used as well as topical treatment of pimecrolimus, which is applied two times daily for 3 months. Topical imiquimod can be used for 8 weeks as well as minoxillin, allopurinol, and oral prednisone at the dose of 30 mg/day [22, 23]. Results of those treatment have not been satisfying although intralesion injection of triamsinolone is more significant for treating the occurring inflammation [24].

Granuloma and remaining fibrosis may also be treated with subdermal injection of triamcinolone acetonide at a dose of 10 mg/ml or a combination of triamcinolone acetonide and 5-fluorouracil. Steroid injection can be performed at the earliest within 2 weeks after wound closure.

The injection is performed once or twice weekly as many as five to seven times. The dose depends on the amount of remaining granuloma and fibrosis, and usually it is at dose of 0.2-0.4 cc per injection.

Etanercept, which works on TNF- α receptor and Fc-IgG1 binding, has been reported providing good result for silicone granuloma [25, 26, 27]. The administration of this drug at the dose of 50 mg

twice weekly or 25 mg of subcutaneous injection two times a week has offered relatively satisfying results [27].

REFERENCES

- 1. Peters W, Fomarsier V. Complication from injectable material used for breast augmentation. The Canadian Journal of Plastic Surgery. 2009; 17(3).89-96
- 2. Harlim A, Aisah S, Sihombing R. Silicon Level in skin tissues of normal female individuals. Journal of Pakistan Association of Dermatologists 2018; 28:2
- 3. Eighteenth Report of the Joint FAO/WHO Expert Committee on Food Additives, Wld Hlth Org. Techn. Rep. Ser., No. 557. FAO Nutrition Meetings Report Series, No. 54. 1974. Available from: http://www.inchem.org/documents/jecfa/jecmono/vo6je42.htm
- 4. Liles DT, Lin F. Silicon Elastomeric Particles in Skin Care Applications, Chapter 11. Vol 1053. Science & Technology Department; 2010. pp 207-219.
- 5. Nair A, Jacob S, Al-Dhublab B, Attimarad M, Harsha S. Basic considerations in the dermatokinetics of topical formulations. Brazilian Journal of Pharmaceuticals Sciences. 2013; 49(3): 423-434
- 6. Alcon Laboratories, Inc. Liquid Silicon Injection. 2010. Available from: <u>http://www.yestheyrefake.net/liquid_silikon_risks.htm</u> [Accessed: August 11, 2010]
- 7. Granuloma. Medterms Online Medical Dictionary [Internet]. 1998. Available from: http://medterms.com [Accessed: 20 March, 2011]
- 8. James DG, Williams WL. Classification of granulomatous disorders: A clinico-pathological synthesis. In: James DG, Zumla A, editors. Granulomatous Disorders. United Kingdom: Cambrige Press; 1999.p.17-27.
- 9. Bondurant S, Ernster V, Herdman R. Antinuclear antibodies and silikone breast implants. In: Safety of Silikon Breast Implants. Washington: The National Academy Press;1999.pp.198-214.
- 10. Lemperle G, Morhenn V, Charrier U. Human histology and persistence of various injectable filler substances for soft tissue augmentation. Aesthetic Plastic Surgery. 2003;27:354-366. DOI:10.1007/s00266-003-3022-1.
- 11. Harlim A, Kanoko M, Aisah S. Classification of foriegn body reaction due to industrial silicone injection. Dermatologic Surgery.2018;9(44):1174-1182
- 12. Price CT, Koval KJ, Langford JR. Silicon: A review of its potential role in the prevention and treatment of postmenopausal osteoporosis. International Journal of Endocrinology. 2013;2013:316783
- 13. Jugdaohsingh R. Silicon and bone health. The Journal of Nutrion, Health & Aging. 2007; 11(2): 99-110.
- 14. James DG. A clinicopathological classification of granulomatous disorders. Postgraduate Medical Journal. 2000;76(898):457-465.
- 15. Agustini C, Semenzato G. Biology and immunology of granuloma. In: James DG, Zumla A, editors. Granulomatous Disorders. United Kindom: Cambrige Press; 1999.pp.3-16.
- 16. Granuloma. Dorland's Medical Dictionary. [Internet]. Saunders & Elsevier; 2007. Available from: <u>http://www.medical-dictionary.thefreedictionary.com.</u> [Accessed: 13 April 2007]
- 17. Pollack SV. Wound healing: A review . IV. Systemic medications affecting wound healing. The Journal of Dermatologic Surgery and Oncology. 1982;8:667-672.
- 18. Adams C, Ratner D. Composite and free cartilage grafting. Dermatologic Clinics 2005;23:129-140, vii.
- 19. Kovich O,Otley CC. Thrombotic complications related to discontinuation of warfarin and aspirin therapy perioperatively for cutaneous operation. Journal of the American Academy Dermatology. 2003;48:233-237.
- 20. Sheen JH, Sheen AP. Aesthetic Rhinoplasty, 2nd ed. St Louis: Quality Medical Publishing, 1998.
- 21. Tardy ME. Rhinoplasty: The Art and the Science. Philadelphia: WB Saunders, 1997.
- 22. Ellis LZ, Cohen JL, High W. Granulomatous reaction to silicone injection. The Journal of Clinical and Aesthetic Dermatology. 2012;5(7);44-7.
- 23. Arin MJ, Bate J, Krieg T, Hunzelmann N. Silicone granuloma of face treated with minocyline. The Journal of American Academy of Dermatology. 2005;52(2): S53-S56.
- 24. Sharma MD, Hou D, Liu Y, Koni PA, Metz R, Chandler P, et al. Indoleamine 2,3-diokxygenase controls conversion of Foxp3+ Tregs to Th17-like cells in tumor-draining lymph nodes. Blood. 2009; 113: 6102-6111.

- Pasternack FR, Fox LP, Engler DE. Silicone granulomas treated with etanercept. Archieves Dermatology. 2005;141(1):13–15.
 Desai AM, Browning J, Rosen T. Etanercept therapy for silicone granuloma. Journal of Drugs in Dermatology. 2006;5(9):894-896
 Styperek A, Bayers S, Beer K. Nonmedical-grade injections of permanent fillers medical and medico-legal considerations. The Journal of Clinical and Aesthetic Dermatology. 2013; 6(41): 20-27.